MiniMed (MMED) Q1 Revenue Beats Estimates Amid Strong US and International Growth
MiniMed (MMED) Q1 revenue beats estimates on strong US and international diabetes device growth
Key points
- MiniMed beats Q1 revenue estimates as standalone spinoff from Medtronic shows strong US and international growth
- Pure-play valuation re-rating thesis validated as market assigns higher multiple to focused diabetes device company
- GLP-1 drug adoption from Ozempic class remains key secular risk for insulin pump addressable market size
Does this change your view on the stock? Share your take below.
Read the full analysis on market.news
🇺🇸 United States Earnings Beat healthcare diabetes medical-devices spinoff